share_log

A Quick Look at Today's Ratings for Atlassian(TEAM.US), With a Forecast Between $275 to $310

Moomoo News ·  Jan 7 21:00  · Ratings

On Jan 07, major Wall Street analysts update their ratings for $Atlassian (TEAM.US)$, with price targets ranging from $275 to $310.

Barclays analyst Ryan MacWilliams maintains with a buy rating, and maintains the target price at $275.

Oppenheimer analyst Ittai Kidron maintains with a buy rating, and adjusts the target price from $270 to $300.

Piper Sandler analyst Rob Owens maintains with a buy rating, and adjusts the target price from $265 to $310.

Truist Financial analyst Joel Fishbein upgrades to a buy rating, and adjusts the target price from $200 to $300.

Here are the latest investment ratings and price targets for $Atlassian (TEAM.US)$ from 4 analysts:

StockTodayLatestRating_mm_203734_20250107_en

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment